COVID-19 and tuberculosis (TB) are currently the top two infectious diseases by mortality. Universally, personnel and financial resources from existing disease control programs have been diverted to the COVID-19 response. For TB, this has resulted in a steep decline in case notifications, and, for the first time since 2015, annual mortality increased. Strategies to simultaneously address both diseases could help recover missing TB cases and ensure people suffering from either disease receive appropriate care. We have undertaken two initiatives towards integrating testing for COVID-19 and TB in Lima, Peru. First, we investigated rapid testing for COVID-19 and TB in one clinical encounter using a molecular multi-disease testing platform that is available through Peru. Second, we are evaluating the use of cough classification artificial intelligence models, with data collected using a smartphone. Clinical and qualitative aspects of the intervention are being assessed. The findings from our studies will likely be generalizable to other urban settings with high TB burdens
